The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL.
 
LaQuisa C Hill
No Relationships to Disclose
 
Rayne H Rouce
Honoraria - Kite/Gilead; Novartis
Research Funding - Tessa Therapeutics (Inst)
 
Tyler S Smith
No Relationships to Disclose
 
Blakely Boriskie
No Relationships to Disclose
 
Madhuwanti Srinivasan
No Relationships to Disclose
 
Sachin G Thakkar
No Relationships to Disclose
 
Huimin Zhang
No Relationships to Disclose
 
Birju Mehta
No Relationships to Disclose
 
Juntima Sritabal-Ramirez
No Relationships to Disclose
 
Bambi J Grilley
Employment - QB Regulatory Consulting; South TexAs Nuclear pharmAcy (I)
Stock and Other Ownership Interests - Allovir
 
Helen E Heslop
Stock and Other Ownership Interests - Allovir; Fresh Wind Biotechnologies; Marker Therapeutics
Consulting or Advisory Role - GlaxoSmithKline; Kiadis Pharma; Marker Therapeutics; Mesoblast; Takara Bio; Tessa Therapeutics
Research Funding - Cell Medica (Inst); Tessa Therapeutics (Inst)
 
Malcolm K Brenner
Stock and Other Ownership Interests - Abintus Bio; Allogene Therapeutics; Allovir; Bellicum Pharmaceuticals; Bluebird Bio; Brooklyn ImmunoTherapeutics; Marker Therapeutics; Memgen; poseida therapeutics; Tessa Therapeutics; TScan Therapeutics; Walking Fish Therapeutics
Honoraria - Merck (I)
Consulting or Advisory Role - Abintus Bio; Adaptimmune; Alimera Sciences; Athenex; Cell Medica (I); Formula Pharmaceuticals; Marker Therapeutics; Memgen; NantWorks; poseida therapeutics; Tessa Therapeutics; torque; TScan Therapeutics; Turnstone Bio; Walking Fish Therapeutics
Research Funding - Cell Medica (I)
Patents, Royalties, Other Intellectual Property - Not applicable because its not related
Travel, Accommodations, Expenses - Bluebird Bio; Merck (I); Tessa Therapeutics; Torque
 
Maksim Mamonkin
Leadership - CSO Pharma; March Biosciences
Stock and Other Ownership Interests - March Biosciences
Honoraria - Amgen
Consulting or Advisory Role - March Biosciences; Xenetic Biosciences
Research Funding - Fate Therapeutics
Patents, Royalties, Other Intellectual Property - Allogene Therapeutics (Inst); Beam Therapeutics; Fate Therapeutics; March Biosciences